Fabhalta: Dosage Form, Projected Sales, NCE-1 Date | Iptacopan

Fabhalta

Fabhalta is an oral capsule that helps treat rare blood and kidney diseases by inhibiting complement factor B. It’s approved for adults with paroxysmal nocturnal hemoglobinuria (PNH), and to reduce proteinuria in complement 3 glomerulopathy (C3G) and IgA nephropathy.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Iptacopan
Innovator :

NOVARTIS PHARMACEUTICALS CORP
Approval Date :

05-Dec-23
NCE-1 Date :

05-Dec-27
NCE Date :

05-Dec-28
Dosage Form :

Capsule
Strength :

200mg
Therapeutic Category :

Immunomodulators
Revenue ($M) :

505

Year-wise Projected Sales ($M) :

2026 :

850
2027 :

1252
2028 :

1669
2029 :

2061
2030 :

2394
2031 :

2711
2032 :

2986

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Fabhalta

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?